Abstract

The Pediatric AIDS Clinical Trials Group (PACTG) is the preeminent organization in the world for evaluating treatments for HlV-infected children and adolescents, and for developing new approaches for the interruption of mother-to-infant transmission. It has set the standards of care for children infected with HIV and for the interruption of vertical transmission. The PACTG is a multicenter, multidisciplinary investigative group. This cooperative agreement concerns the PACTG Coordinating and Operations Center (CORC), which includes support for the Group Leader, the Executive Committee, Other standing committees, a Community Constituency Group, the Operations Center, and the core and developmental laboratories. Associated with the CORC, under separate applications, are 18-25 pediatric AIDS Clinical Trials Units and a Statistical and Data Management Center. The Group will be managed by an Executive Committee which will oversee an integrated research agenda developed by four Research Agenda Committees (Perinatal Transmission, primary Therapy, Opportunistic Infections, and Immunology/Immune-Based Therapy (IBT)], three Scientific Committees (Virology, Immunology, and Pharmacology), and five Resource Committees (Neurology/Neuropsychology, Adolescent, Community Constituency Group, Supportive Care/Quality of Life, and Site Advisory Core Committee). The scientific agenda of the PACTG encompasses the critical issues that impact mother-to-infant transmission and treatment of HIV-infected children and adolescents. The three primary goals of the PACTG's scientific agenda are (l) to decrease mother-to-infant transmission of HIV to less than 2%, (2) to achieve a 90% 10-year survival for children perinatally infected with HIV, and (3) to develop novel strategies for early treatment of newly-infected infants and adolescents. The structure of the PACTG has been designed to provide a mechanism for a coordinated response to rapidly changing investigative opportunities for HIV-infected infants, children, adolescents, and pregnant women.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI041089-04
Application #
6163720
Study Section
Special Emphasis Panel (ZAI1-PRJ-A (01))
Program Officer
Batzold, Frederick
Project Start
1997-03-01
Project End
2002-02-28
Budget Start
2000-03-01
Budget End
2002-02-28
Support Year
4
Fiscal Year
2000
Total Cost
$9,031,018
Indirect Cost

  Institution

Name
Social and Scientific Systems, Inc.
Department
Type
DUNS #
City
Silver Spring
State
MD
Country
United States
Zip Code
20910

  Publications

Aweeka, F T; Hu, C; Huang, L et al. (2015) Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med 16:176-83
Olson, Scott C; Ngo-Giang-Huong, Nicole; Beck, Ingrid et al. (2015) Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission. AIDS 29:1467-71
Qin, Min; Brummel, Sean; Singh, Kumud K et al. (2014) Associations of host genetic variants on CD4? lymphocyte count and plasma HIV-1 RNA in antiretroviral naïve children. Pediatr Infect Dis J 33:946-52
Buckoreelall, Kajal; Cressey, Tim R; King, Jennifer R (2012) Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet 51:639-59
Saitoh, Akihiko; Capparelli, Edmund; Aweeka, Francesca et al. (2010) CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 54:285-9
Huang, Yangxin; Wu, Hulin; Acosta, Edward P (2010) Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors. Biom J 52:470-86
Aldrovandi, Grace M; Lindsey, Jane C; Jacobson, Denise L et al. (2009) Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 23:661-72
Aldrovandi, Grace M; Chu, Clara; Shearer, William T et al. (2009) Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics 124:e1189-97
Valente, Thomas W; Zogg, Jennifer B; Christensen, Shawna et al. (2009) Using social networks to recruit an HIV vaccine preparedness cohort. J Acquir Immune Defic Syndr 52:514-23
Bryson, Y J; Mirochnick, M; Stek, A et al. (2008) Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials 9:115-25

Showing the most recent 10 out of 84 publications